2Herszenyi L, Farinati F, Miheller P, et al. Chemoprevention of colorectal cancer: feasibility in everyday practice?[J]. Eur J Cancer Prey, 2008,17(6): 502-514.
3Rudolph G, Kloeters-Plachky P, Rest D, et al. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid[J]. Eur J Gastroenterol Hepatol, 2007,19(6): 487-491.
4Chapman R, Fevery J, Kalloo A, et al. Diagnosis and man agement of primary sclerosing cholangitis[J]. Hepatology, 2010, 51(2): 660-678.
5Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury[J]. Hepatology, 2007, 45(5): 1306-1312.
6Lu SC, Mato JM. S-Adenosylmethionine in cell growth, apop tosis and liver cancer[J], J Gastroenterol Hepatol, 2008, 23(Suppl 1): S73-77.
7Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis[J]. Cochrane Patabase Syst Rev, 2010, 20(1 ):CD004036.
8Arulprakash S, Sasi AD, Bala MR, et al. Overlap syndrome: autoimmune hepatitis with primary biliary cirrhosiS[J]. J Assoc Physicians India, 2010, 58: 455-456.
9Sandborn W J, Wiesner RH, Tremaine W J, et al. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin[J]. Gut, 1993, 34(2): 242-246.
10Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus(FK 506), a treatment for prima-ry sclerosing cholangitis: results of an open-label preliminary trial[J]. Am J Gastroenterol, 1995, 90(3): 455-459.
